Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular determinants for the activity of the novel CD33/CD3-directed bispecific T-cell engager antibody, AMG 330. In the presence of T cells, AMG 330 was high...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Laszlo, George S., Gudgeon, Chelsea J., Harrington, Kimberly H., Dell’Aringa, Justine, Newhall, Kathryn J., Means, Gary D., Sinclair, Angus M., Kischel, Roman, Frankel, Stanley R., Walter, Roland B.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901068/
https://ncbi.nlm.nih.gov/pubmed/24311721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-527044
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars